baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

REGENERON PHARMAC.DL-,001/ US75886F1075 /

2024-07-27 1:04:14 PM	Chg. 0.00	Volume	Bid1:04:14 PM	Ask1:04:14 PM	Market Capitalization	Dividend Y.	P/E Ratio
988.80EUR	0.00%	- Turnover: -	988.80Bid Size: -	998.60Ask Size: -	109.46 bill.EUR	-	-

GlobeNewswire 06-28 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 06-27 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 06-26 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 06-16 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...

GlobeNewswire 06-11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 05-23 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 05-17 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 05-08 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 05-06 Regeneron Announces Investor Conference Presentations

GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 04-29 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 04-25 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 04-24 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 04-22 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

GlobeNewswire 04-07 Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in ...

GlobeNewswire 04-01 Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and ...

GlobeNewswire 03-25 Regeneron Provides Update on Biologics License Application for Odronextamab

GlobeNewswire 03-13 High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...

GlobeNewswire 03-11 Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...

GlobeNewswire 03-08 EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...

GlobeNewswire 02-23 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...

REGENERON PHARMAC.DL-,001/ US75886F1075 /

If you wish to receive reply to your feedback, please provide your email address.